Medigus: Eventer Technologies Secured $2.25 Million in Pre-IPO Funding Round
April 08 2021 - 8:00AM
Medigus Ltd. (NASDAQ:MDGS), a technology company
engaged in advanced medical solutions and innovative technology,
announced today that Eventer Technologies Ltd., Medigus’ subsidiary
(58.77% prior to funding round) and developer of advanced
technology solutions for creating, marketing and managing an
events, including virtual events, successfully completed a pre-IPO
funding round of $2.25 million. The current investment round is
part of Eventer's intention to conduct an initial public offering
of its shares on the Tel Aviv Stock Exchange.
Medigus invested six months ago $750,000 in
Eventer for 58.77% of the company. Following $300,000 of additional
investment by Medigus as part of this $2.25 million round, Medigus
now owns 47.69% of Eventer, reflecting value of $6 million for
Medigus in Eventer post money.
The funding round includes an investment of $1.5
million from Keshet, a leading Israeli broadcasting and media
group. According to the investment agreement, half of the proceeds
will be used for promotion of Eventer’s business through media
content and space advertising in different platforms and media
outlets operated by such broadcasting and media group. Eventer
intends to use such media content and space advertising to further
promote its virtual events and conferences solutions.
Eventer enables producers to create events,
manage ticket operations and boost ticket sales, all in one
efficient and cost-effective platform. As a result of its exclusive
collaboration with Screenz' Cross Media Ltd. platform, Eventer will
be able to offer a leading product that would specialize in digital
and interactive broadcasting. Screenz is a virtual entertainment
and events technology company, whose customer base, past and
present, includes Reliance Industries (a Fortune 500 company and
the largest private sector corporation in India), Fox, ABC, Disney,
Univision, Viacom and many more.
About Medigus
Medigus is traded on the Nasdaq Capital Market.
To learn more about the company’s advanced technology, please
visit www.medigus.com.
Cautionary Note Regarding Forward Looking
Statements
This press release may contain statements that
are “Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of Medigus’ management and
its knowledge of the relevant market. The company has tried, where
possible, to identify such information and statements by using
words such as “anticipate,” “believe,” “envision,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“contemplate” and other similar expressions and derivations thereof
in connection with any discussion of future events, trends or
prospects or future operating or financial performance, although
not all forward-looking statements contain these identifying words.
For example, Medigus uses forward looking statements when
describing Eventer’s intention to list its securities on the Tel
Aviv Stock Exchange, Medigus’ share in Eventer following the
closing of the funding round, the anticipated use and benefit to
Eventer and Screenz and their prospective users, and the belief
that Eventer has the opportunity to become a key player
in the market in a relatively short time. These forward-looking
statements represent Medigus’ expectations or beliefs concerning
future events, and it is possible that the results described in
this press release will not be achieved. By their nature,
Forward-Looking Statements involve known and unknown risks,
uncertainties and other factors which may cause future results of
the Eventer’s activity to differ significantly from the content and
implications of such statements. Other risk factors affecting
Medigus and Eventer are discussed in detail in the Medigus’ filings
with the Securities and Exchange Commission. Forward-Looking
Statements are pertinent only as of the date on which they are
made, and Medigus undertakes no obligation to update or revise any
Forward-Looking Statements, whether as a result of new information,
future developments or otherwise. Neither Medigus nor its
shareholders, officers and employees, shall be liable for any
action and the results of any action taken by any person based on
the information contained herein, including without limitation the
purchase or sale of Medigus’ securities. Nothing in this press
release should be deemed to be medical or other advice of any
kind.
Investor Contact
Oz AdlerChief Financial Officer+972-8-6466-880ir@medigus.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Apr 2023 to Apr 2024